Intercept Pharmaceuticals Inc (OQ:ICPT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 10 Hudson Yards Fl 37
NEW YORK NY 10001-2160
Tel: N/A
IR: See website
Key People
Paolo Fundaro
Independent Chairman of the Board
Lisa DeFrancesco
Vice President of Investor Relations
Mark Pruzanski
President, Chief Executive Officer, Director
Sandip S. Kapadia
Chief Financial Officer, Treasurer
Lisa Bright
President, International
Richard Kim
President, U.S. Commercial & Strategic Marketing
Jerome Benedict Durso
Chief Operating Officer
David A. Ford
Chief Human Resource Officer
Christian Weyer
Executive Vice President - Research & Development
Gail Cawkwell
Senior Vice President - Medical Affairs, Safety & Pharmacovigilance
Business Overview
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
Financial Overview
For the fiscal year ended 31 December 2019, Intercept Pharmaceuticals Inc revenues increased 40% to $252M. Net loss increased 11% to $344.7M. Revenues reflect Licensing revenue increase of 20% to $2.4M. Higher net loss reflects General & Administrative increase of 20% to $260.4M (expense), Research & development increase of 17% to $230M (expense), Interest expense increase of 35% to $41.1M (expense).
Employees: 583 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,857M as of Dec 31, 2019
Annual revenue (TTM): $252.00M as of Dec 31, 2019
EBITDA (TTM): -$308.73M as of Dec 31, 2019
Net annual income (TTM): -$344.68M as of Dec 31, 2019
Free cash flow (TTM): -$237.75M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 32,853,066 as of Dec 31, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization